Key Highlights
● VRTX shares ended 9 October 2026 at $510.08.
● Market data consensus target is $579.81, implying about 13.7% upside.
● The second data set shows a mean of $571.61 and a median of $578.
● Morgan Stanley initiated coverage on 1 September with a $665 target.
Vertex Pharmaceuticals (NASDAQ:VRTX), a constituent of both the S&P 500 and the Nasdaq-100, finished Friday 9 October 2026 at $510.08. The consensus target sits moderately above the share price.
What Is the Latest Analyst Price Target?
Market data reports a consensus 12-month price target of $579.81 from 28 analysts, with a high of $665 and a low of $442, implying upside of about 13.7%. The second data set shows a mean of $571.61, a median of $578, a high of $672 and a low of $350 from 32 analysts, implying about 12%.
What Are Wall Street Analysts Saying?
Market data counts 25 Buy-category ratings and three Hold ratings, with no Sell ratings, while the second data set lists one Strong Sell among 32 analysts. Recent broker actions include RBC raising its target from $570 to $576 on 8 October 2026, UBS from $585 to $615 on 28 September, Jefferies from $633 to $640 and TD Cowen from $525 to $550 on 23 September, and Leerink Partners initiating at Outperform with $594 on 21 September. Morgan Stanley initiated at Overweight with a $665 target on 1 September, and JPMorgan raised its target from $515 to $560 on 11 September.
What Could Help the Stock Reach the Price Target?
Target revisions in the past six weeks have been overwhelmingly upward, and new coverage has been initiated at higher levels. Market data reports second-quarter revenue of $3.33bn, up 12.5% year on year. Sanford C. Bernstein was also recorded upgrading its rating on 29 July. If revenue growth continues, analysts' upward revisions could be vindicated. The consensus target suggests upside of about 13.7% from the closing price.
What Could Prevent the Stock Reaching the Target?
Canaccord Genuity and Stifel rate the shares Hold, with targets of $442 and $500, both below the consensus. Market data reports earnings per share of $4.73, marginally below the $4.74 consensus. Pharmaceutical companies also face clinical, regulatory and pricing risks that can shift forecasts quickly.
What Should Investors Watch Next?
Further target changes from the brokers named above would also be informative.
Vertex Pharmaceuticals and the Gap to Analyst Targets
Vertex Pharmaceuticals closed at $510.08 on 9 October 2026, against a market data consensus target of $579.81. Morgan Stanley initiated at Overweight with a $665 target on 1 September, and JPMorgan raised its target from $515 to $560 on 11 September.






Please wait processing your request...